Radiotherapy is one of the most effective modalities for cancer treatment, but radiation-associated secondary malignancies are important potential morbidities. Here, we highlight a recent article that examines radiation-associated muscle-invasive bladder cancer and explore how we as clinicians should consider the management of secondary malignancies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Association of different treatment modalities for rectal cancer and second primary urinary system neoplasms, findings from SEER
Scientific Reports Open Access 29 May 2025
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Parker, R. G. Radiation-induced cancer as a factor in clinical decision making (the 1989 ASTRO Gold Medal Address). Int. J. Radiat. Oncol. Biol. Phys. 18, 993–1000 (1990).
Hall, E. J. & Wuu, C.-S. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int. J. Radiat. Oncol. Biol. Phys. 56, 83–88 (2003).
Eaton, B. R., MacDonald, S. M., Yock, T. I. & Tarbell, N. J. Secondary malignancy risk following proton radiation therapy. Front. Oncol. 5, 261 (2015).
Schneider, U. et al. The impact of IMRT and proton radiotherapy on secondary cancer incidence. Strahlenther. Onkol. 182, 647–652 (2006).
Sha, S. T. et al. Clinical characterization of radiation-associated muscle-invasive bladder cancer. Urology https://doi.org/10.1016/j.urology.2021.03.033 (2021).
Goldberg, Z. Clinical implications of radiation-induced genomic instability. Oncogene 22, 7011–7017 (2003).
Dores, G. M. et al. Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J. Clin. Oncol. 20, 3484–3494 (2002).
Lee, C.-L. et al. Mutational landscape in genetically engineered, carcinogen-induced, and radiation-induced mouse sarcoma. JCI Insight 4, e128698 (2019).
Yamamoto, S. et al. Specific p53 gene mutations in urinary bladder epithelium after the Chernobyl accident. Cancer Res. 59, 3606–3609 (1999).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests
Rights and permissions
About this article
Cite this article
Reddy, V.K., Vapiwala, N. Secondary malignancy after radiotherapy: not always a secondary concern. Nat Rev Urol 18, 513–514 (2021). https://doi.org/10.1038/s41585-021-00486-w
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41585-021-00486-w
